Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of omalizumab withdrawal after 3 years in well-controlled severe allergic asthma
2020-000883-42Phase 4Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of omalizumab in allergic asthma (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Started Aug 2020; status: active.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2020-000883-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000883-42.